<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910945</url>
  </required_header>
  <id_info>
    <org_study_id>AI0620</org_study_id>
    <nct_id>NCT04910945</nct_id>
  </id_info>
  <brief_title>Mechanical Coring to Achieve Directional Skin Tightening</brief_title>
  <official_title>Pilot Study for the Clinical Evaluation of Mechanical Coring to Achieve Directional Skin Tightening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venus Concept</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Venus Concept</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the safety and efficacy of mechanical&#xD;
      coring for directional skin tightening. This study is a prospective, up to three center,&#xD;
      multiple skin treatment area study of the safety and efficacy of mechanical coring with&#xD;
      directional closure to achieve directional skin tightening. The study will evaluate the&#xD;
      progress of up to 40 subjects after one treatment at up to 6 treatment areas on the body (two&#xD;
      on each underarm and one periauricular). Subjects will be followed at 2, 7, 14, 28, 60 and 90&#xD;
      days after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, up to three center, multiple skin treatment area study of the safety and&#xD;
      efficacy of mechanical coring with directional closure to achieve directional skin&#xD;
      tightening. The study will evaluate the progress of up to 40 subjects after one treatment at&#xD;
      up to 6 treatment areas on the body (two on each underarm and one periauricular). Subjects&#xD;
      will be followed at 2, 7, 14, 28, 60 and 90 days after treatment. Analysis will be performed&#xD;
      on all subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Skin Tightening</measure>
    <time_frame>3 Months</time_frame>
    <description>Percentage of directional skin tightening achieved at each of the skin treatment sites by day 7, 14, 28, 60 and 90 based on the change in the area defined by tattoo marks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Cores Successfully Removed by Coring Device</measure>
    <time_frame>1 day</time_frame>
    <description>Percentage of cores successfully removed by the coring device without manual removal.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Visual Analog Scale (VAS) Pain Scale</measure>
    <time_frame>1 day</time_frame>
    <description>Subject's assessment of discomfort and pain after treatments as measured by a VAS Pain Scale on 10 cm line. 0 cm being no pain/no discomfort and 10 cm being excruciating and unbearable pain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment Related Adverse Event (AE)</measure>
    <time_frame>3 Month</time_frame>
    <description>Subjects experiencing a treatment-related adverse event (AE) in the first 90 days post-treatment.</description>
  </other_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Skin Tightening</condition>
  <condition>Healthy Volunteers</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VENUS AIME (RoboCor)</intervention_name>
    <description>VENUS AIME is a micro-coring device of the skin that can potentially help to reduce visible skin scarring, improve skin laxity and reduce wrinkles.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, male or female subjects between 30 and 70 years of age.&#xD;
&#xD;
          2. Able to read, understand and voluntarily provide written Informed Consent.&#xD;
&#xD;
          3. Able and willing to comply with the treatment/follow-up schedule and requirements.&#xD;
&#xD;
          4. Women of childbearing age are required to be using a reliable method of birth control&#xD;
             at least 3 months prior to study enrollment and for the duration of the study and have&#xD;
             a negative Urine Pregnancy test at baseline.&#xD;
&#xD;
          5. Subjects may have any Fitzpatrick skin type, however, no more than 25% of subjects may&#xD;
             have Fitzpatrick skin type V or VI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous aesthetic (device and/or surgical) skin treatment in the treated areas (under&#xD;
             arms and/or behind the ear) in the previous 6 months.&#xD;
&#xD;
          2. Fat, collagen, silicone, tattoos, body jewelry, that cannot be removed for the&#xD;
             duration of treatment and tegaderm/glue application or any other synthetic material in&#xD;
             the treatment area.&#xD;
&#xD;
          3. History of keloid formation&#xD;
&#xD;
          4. Active smoker or having quit smoking in the last 3 months.&#xD;
&#xD;
          5. Active, chronic, or recurrent infection&#xD;
&#xD;
          6. Compromised immune and/or healing system (e.g. diabetes)&#xD;
&#xD;
          7. Hypersensitivity/allergy to analgesic agents.&#xD;
&#xD;
          8. Co-morbid condition that could limit the ability to participate in the study or to&#xD;
             comply with follow-up requirements.&#xD;
&#xD;
          9. Pregnant or breastfeeding&#xD;
&#xD;
         10. Any indication that may cause excessive bleeding, e.g., anticoagulants.&#xD;
&#xD;
         11. Carcinoma, melanoma, or any other cancerous condition in the last 6 months.&#xD;
&#xD;
         12. Allergy to adrenaline, epinephrine, or Tranexamic acid (TXA).&#xD;
&#xD;
         13. Currently or in the last 1-month part of another clinical study of an investigational&#xD;
             drug and/or experimental medical device&#xD;
&#xD;
         14. Any issue that, at the discretion of the investigator would contra-indicate the&#xD;
             subject's participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Gronski</last_name>
    <role>Study Director</role>
    <affiliation>Venus Concept</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rathana Yim</last_name>
    <phone>888-907-0115</phone>
    <email>ryim@venusconcept.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Gronski</last_name>
    <phone>888-907-0115</phone>
    <email>mgronski@venusconcept.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Berman Skin Institute</name>
      <address>
        <city>Los Altos</city>
        <state>California</state>
        <zip>94022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Berman, M.D.</last_name>
      <phone>650-325-6000</phone>
      <email>david.berman@skinmds.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna Marte</last_name>
      <phone>(650) 325-6000</phone>
      <email>anna.marte@skinmds.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Berman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steve Dayan</last_name>
      <phone>312-335-2070</phone>
    </contact>
    <investigator>
      <last_name>Steven Dayan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhytides</keyword>
  <keyword>Wrinkles</keyword>
  <keyword>Loose Skin</keyword>
  <keyword>Skin Laxity</keyword>
  <keyword>Mechanical Coring</keyword>
  <keyword>Robotic Coring</keyword>
  <keyword>Skin Scarring</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 22, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT04910945/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT04910945/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

